Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Pruxelutamide by Kintor Pharmaceutical for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Pruxelutamide is under clinical development by Kintor Pharmaceutical and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData,...